A Group Intervention for Promoting Health-related Habits (LEV-G)
Launched by REGION STOCKHOLM · May 5, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The LEV-G clinical trial is studying a group program designed to help people improve their health-related habits, which can have a positive impact on both mental and physical well-being. Many individuals struggle with making healthy lifestyle choices, and this project aims to provide effective support for those who need it. The program is suitable for adults, including those with various disabilities, and seeks to make health care more accessible and effective for everyone.
To take part in the trial, participants should be adults aged between 18 and 80, with or without disabilities. However, those with severe intellectual disabilities, significant language barriers, or serious mental health issues may not be eligible. If you join this study, you can expect to participate in group sessions that focus on building healthier habits in a supportive environment. This trial is currently recruiting participants, and it's a great opportunity for individuals looking to make positive changes in their lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • both adults with and without disabilities recruited from different healthcare contexts.
- Exclusion Criteria:
- • Intellectual disability of the degree where the participant is not able to follow the protocol in Lev.
- • Insufficient command of the Swedish language/ unable to understand the content.
- • Severe psychiatric comorbidity that makes participation difficult (e.g. severe depression, severe suicidality, severe anxiety, ongoing psychosis, manic episode), other circumstances that could make participation hard (e.g. homelessness).
About Region Stockholm
Region Stockholm is a leading healthcare authority committed to advancing medical research and improving patient care through innovative clinical trials. As a sponsor, Region Stockholm collaborates with hospitals, research institutions, and industry partners to facilitate the development of new therapies and treatment protocols. With a focus on quality, safety, and ethical standards, the organization aims to enhance health outcomes for the diverse population of Stockholm and beyond, leveraging cutting-edge research to translate scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, Stockholm, Sweden, Sweden
Stockholm, , Sweden
Patients applied
Trial Officials
Douglas Sjöwall, PhD
Principal Investigator
Region Stockholm
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported